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Available online 29 October 2016Background: Vascular endothelial growth factor (VEGF) signaling is an important pathway in the development of
diabetic retinopathy (DR). A recent report showed that leukocyte cell-derived chemotaxin 2 (LECT2) suppresses
the VEGF signaling in endothelial cells. However, the clinical relevance of LECT2 in DR is unknown. This study
aimed to investigate serum LECT2 levels and the presence of DR.
Methods: The study included 230 people with type 2 diabetes mellitus (DM), 95 with DR and 135 without DR.
Serum LECT2 levels were measured using an enzyme-linked immunosorbent assay. Data were evaluated using
Spearman's rank correlation, univariate and multivariate logistic regression.
Results: Serum LECT2 levels were signiﬁcantly lower in participants with DMhaving DR than in those not having
DR (35.6 ± 14.9 ng/ml vs. 44.5 ± 17.6 ng/ml, P b 0.001). Spearman's rank correlation analysis revealed a signif-
icant association between serum LECT2 levels and the presence of DR (P b 0.001). Multiple regression analysis
revealed that serum LECT2 levels were independently related to DR (P b 0.001).
Conclusions: These ﬁndings indicated that serum LECT2 level is negatively associatedwith the presence of DR and
suggest that low circulating LECT2 level is a risk factor for DR.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Type 2 diabetes mellitus1. Introduction
Diabetic retinopathy (DR) is a seriousmicrovascular complication of
diabetes mellitus (DM) and the leading cause of visual impairment in
people with DM [1]. The retinal extracellular ﬂuid and/or circulating
concentrations of proinﬂammatory cytokines and proangiogenic
growth factors, such as tumor necrosis factorα and vascular endotheliale inhibitor; ARB, angiotensin
iabetes mellitus; DN, diabetic
R, diabetic retinopathy; FPG,
emotaxin 2; PDR, proliferative
tinopathy; SBP, systolic blood
r endothelial growth factor.
mplications, Diabetes Research
Health and Medicine, 1-21-1
. This is an open access article undergrowth factor (VEGF), are upregulated in peoplewith DR [2,3]. These in-
ﬂammatory factors, whichmay lead to chronicmicro-inﬂammation and
the inﬂux of leukocytes, are proposed to contribute to the onset and
progression of DR [4,5]. VEGF is an important inﬂammatory and angio-
genic factor thatmediates endothelial cell proliferation, vascular perme-
ability and cell motility. Anti-VEGF therapy is currently effective for DR,
indicating a critical role for VEGF in the pathogenesis of this disease [6].
Some systemic factors had an effect on the onset and progression of
DR, including blood pressure, dyslipidemia, and renal dysfunction [7]. In
addition, circulating concentrations of hepatocyte-secreted mannose-
binding lectin and adipocyte-secreted apelin-13 were associated with
DR [8,9]. On the other hand, high circulating glycodelin prevents the
progression of DR in pregnant women with diabetes [10]. Glycodelin
has immunosuppressive properties and is secreted by the mammary
glands and endometrium. These reports indicate that not only intraocu-
lar but also systemic factors play an important role in the development
of DR.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ma protein and is mainly expressed in perivenous hepatocytes [11–14].
It was originally identiﬁed from the culture ﬂuid of the human T cell line
SKW-3 during screening for a novel neutrophil chemotactic protein
[15]. In humans, there is an association between fatty liver disease and
systemic insulin resistance. The livermay contribute to the insulin resis-
tance of skeletal muscle by releasing secretory proteins, now called
hepatokines, including LECT2, an energy-sensing hepatokine. Serum
LECT2 concentrations are positively correlatedwith the severity of insu-
lin resistance and obesity [16,17]. The involvement of LECT2 in glucose
metabolism was recently demonstrated, and it was suggested that
LECT2 is a therapeutic target or prognostic marker for obesity-associat-
ed insulin resistance [17]. The exact molecular mechanism of LECT2
function in obesity and insulin resistance remains to be established by
further studies. However, we and others have reported that LECT2 ex-
erts an immunomodulatory effect in hepatitis, inﬂammatory arthritis,
bacterial sepsis, and hepatic carcinogenesis [18–21]. Furthermore, two
studies reported that LECT2 expression concentrationswere signiﬁcant-
ly lower in human hepatocellular carcinoma (HCC) with vascular inva-
sion than in HCCwithout vascular invasion [22,23]. Most recently, Chen
et al. reported that LECT2 inhibits VEGF165-induced angiogenesis
through direct binding to VEGF receptor-2 (VEGFR2) [24]. These studies
suggest that LECT2 is an anti-angiogenic factor.Table 1
Characteristics of the participants.
Non-DR DR P value
n 135 95
Women [%] 41 [30.4%] 32 [33.7%] NS
Age (y) 60.8 ± 6.4 61.1 ± 6.2 NS
Duration of DM (y) 11.2 ± 7.4 13.6 ± 9.8 0.036
BMI (kg/m2) 25.5 ± 3.9 25.1 ± 4.6 NS
SBP (mm Hg) 126 ± 13 131 ± 18 0.013
DBP (mm Hg) 74 ± 10 73 ± 12 NS
HDL cholesterol (mg/dl) 53 ± 16 51 ± 15 NS
TGs (mg/dl) 123 (91–179) 110 (76–145) 0.017
FPG (mg/dl) 145 ± 42 147 ± 47 0.752
HbA1c (%) 7.4 ± 1.0 7.7 ± 1.3 0.036
ALT (U/l) 30 ± 18 27 ± 20 0.259
γ-GTP (U/l) 30 (21–46) 23 (17–35) 0.0212. Materials and methods
2.1. Study participants
For this cross-sectional study, 230 Japanese people with type 2 DM
(157 men and 73 women aged 40–69 y) were recruited from the De-
partment of Diabetes, Endocrinology, and Metabolism at the National
Center for Global Health and Medicine (Tokyo, Japan) between August
2010 and September 2012. Type 2 DM was diagnosed according to the
Japan Diabetes Society criteria [25]. The duration of diabetes mellitus
(DM) was estimated through interviews. Patient demographics, clinical
characteristics, and laboratory data were obtained from the medical re-
cords. All participants were evaluated for the presence of diabetic mi-
crovascular complications. Diabetic retinopathy was diagnosed by
expert ophthalmologists, and each participant was graded according
to the following categories: no diabetic retinopathy, simple diabetic ret-
inopathy (SDR), pre-proliferative diabetic retinopathy (PPDR) or prolif-
erative diabetic retinopathy (PDR). Diabetic peripheral neuropathy
(DPN) was diagnosed by the presence of two or more of the clinical
symptom components (bilateral spontaneous pain, hypoesthesia, or
paresthesia of the legs), the absence of ankle tendon reﬂexes, and de-
creased vibration sensations when tested with a C-128 tuning fork
[26]. Diabetic nephropathy (DN) was diagnosed as a spot urinary albu-
min-to-creatinine ratio greater than or equal to 30 mg/g [27]. Patients
were excluded from this study if they met any of the following criteria:
(1) blindness; (2) neurologic disorders unrelated to diabetic neuropa-
thy or use of prosthetic limbs; (3) dialysis or renal transplantation; (4)
the obvious macrovascular complications, such as stroke, angina, and
myocardial infarction; and (5) missing values in any variable. This
study was conducted with the approval of the ethical committee of
the National Center for Global Health and Medicine and performed ac-
cording to the Declaration of Helsinki. Written informed consent was
obtained from each participant prior to study enrollment.Insulin therapy [%] 13 [9.6%] 29 [30.5%] b0.001
Biguanide [%] 92 [68.1%] 61 [64.2%] NS
Statin [%] 58 [43.0%] 44 [46.3%] NS
Fibrate [%] 12 [8.9%] 6 [6.3%] NS
ACE-I and/or ARB [%] 54 [40.0%] 48 [50.5%] NS
DPN [%] 58 [43.0%] 67 [70.5%] b0.001
DN [%] 47 [34.8%] 55 [57.9%] b0.001
Values are presented as means ± SD for normally distributed data and as median (inter-
quartile range) for non-normally distributed data (i.e., for TGs and γ-GTP).2.2. Measurement of serum LECT2 concentrations
Serum LECT2 concentrations were measured according to a previ-
ously reported method using a commercially available human LECT2
enzyme-linked immunosorbent assay system (Medical & Biological Lab-
oratories, Nagoya, Japan) [16].2.3. Statistical analyses
The results are presented as mean ± SD. Data were analyzed using
IBM SPSS Statistics ver. 20. The normality of the continuous variables
was analyzed using the Shapiro–Wilk test, and differences between
two groups were examined by the two-tailed unpaired Student's t-test
or the nonparametric Mann–Whitney U test as appropriate. Multiple
comparisons between groups were performed using one-way analysis
of variance (ANOVA). The χ2was used for the analysis of categorical var-
iables. Spearman's rank correlation coefﬁcients were used to evaluate
associations between serum LECT2 concentrations and continuous var-
iables. In the logistic regression analysis, a logarithmic transformation
was applied to the distribution of triglycerides (TGs) and γ-glutamyl
transpeptidase (γ-GTP) to approximate a normal distribution. A
P b 0.05 were considered statistically signiﬁcant.3. Results
3.1. Characteristics of the study population
The clinical characteristics of the participants are presented in Table
1. The participants with DR had longer duration of DM (P = 0.036),
higher systolic blood pressure (SBP, P = 0.013) and hemoglobin A1c
(HbA1c, P = 0.036), and lower TGs (P = 0.017) and γ-GTP (P =
0.021). There was no signiﬁcant difference between the groups with
and without DR in gender, age, body mass index (BMI), diastolic blood
pressure (DBP), high-density lipoprotein (HDL) cholesterol, fasting
plasma glucose (FPG), or alanine transaminase (ALT). The frequency
of patients using insulinwas signiﬁcantly higher among the participants
with DR than in those without (P b 0.001). There was no signiﬁcant dif-
ference in the frequency of the use of biguanide, statin, ﬁbrate, angio-
tensin converting enzyme inhibitor (ACE-I), and angiotensin receptor
blocker (ARB) between the two groups. Diagnoses of DPN and DN
were made in 125 (54.3%) and 102 (44.3%) participants, respectively,
with 1.6- and 1.7-fold higher incidences in the participants with DR
(both P b 0.001). Overall, this analysis indicates that the study popula-
tions of participants with and without DR were balanced in terms of
gender, age, and BMI.
Table 2
Spearman's rank correlation coefﬁcients between serum LECT2 levels and clinical
parameters.
Variable Simple correlation Adjusted for age,
gender, duration of
DM, and BMI
ρ P value Partial ρ P value
Gender (0, man; 1, woman) 0.129 0.051 – –
Age −0.025 NS – –
Duration of DM −0.082 NS – –
BMI 0.256 b0.001 – –
SBP −0.062 NS −0.057 NS
DBP 0.026 NS 0.022 NS
HDL cholesterol −0.164 0.013 −0.175 0.008
TGsa 0.164 0.013 0.121 NS
FPG 0.033 NS 0.051 NS
HbA1c 0.019 NS 0.046 NS
ALT 0.157 0.017 0.158 0.018
γ-GTPa 0.215 0.001 0.176 0.008
Insulin therapy (0, no; 1, yes) −0.153 0.020 −0.096 NS
Biguanide (0, no; 1, yes) 0.061 NS 0.049 NS
Statin (0, no; 1, yes) 0.095 NS 0.103 NS
Fibrate (0, no; 1, yes) 0.050 NS 0.057 NS
ACE-I and/or ARB (0, no; 1, yes) −0.005 NS −0.044 NS
DR (0, no; 1, yes) −0.252 b0.001 −0.250 b0.001
DPN (0, no; 1, yes) 0.035 NS 0.054 NS
DN (0, no; 1, yes) −0.070 NS −0.049 NS
a Log scale.
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tients with and without retinopathy
Serum LECT2 concentrations were signiﬁcantly lower in the partici-
pants with DR compared to those without (35.6 ± 14.9 vs. 44.5 ±
17.6 ng/ml, P b 0.001) (Fig. 1A). Consequently, we compared serum
LECT2 concentrations between the different stages of DR (Fig. 1B).
Serum LECT2 concentrations of participants with SDR (n = 65), PPDR
(n = 10), and PDR (n = 20) were 36.0 ± 15.7, 29.7 ± 12.1, and
37.3 ± 13.3 ng/ml, respectively. These differences were not statistically
signiﬁcant. These results suggest that serum LECT2 concentrations are
not correlatedwith the stage of DR, but are associatedwith the presence
of DR.
3.3. Impact of clinical parameters, medications, diabetic neuropathy, and
diabetic nephropathy on serum LECT2 concentrations
Table 2 presents the results of correlation analyses to determine
whether clinical parameters and other diabeticmicrovascular complica-
tions, i.e., DPN and DN, were associated with serum LECT2 concentra-
tions. Serum LECT2 concentrations were signiﬁcantly correlated with
BMI (ρ= 0.256, P b 0.001), HDL cholesterol (ρ=−0.164, P= 0.013),
log-transformed TGs (ρ = 0.164, P = 0.013), ALT (ρ = 0.157, P =
0.017), log-transformed γ-GTP (ρ= 0.215, P= 0.001), insulin therapy
(ρ = −0.153, P = 0.020) and the presence of DR (ρ = −0.252,
P b 0.001), but not with gender, age, duration of DM, SBP, DBP, FPG,
HbA1c, oral medications (biguanide, statin, ﬁbrate, ACE-I, and ARB),
DPN, or DN. After adjustment for gender, age, duration of DM, and
BMI, the correlations with serum LECT2 concentration that remained
signiﬁcant were those with HDL cholesterol (partial ρ=−0.175, P=
0.008), ALT (partial ρ=0.158, P=0.018), log-transformedγ-GTP (par-
tial ρ=0.176, P=0.008), and the presence of DR (partial ρ=−0.250,
P b 0.001). These results indicated that serum LECT2 concentration is
only associatedwith the presence of DR and notwith DPN and DN in di-
abetic microvascular complications.
3.4. Association of serum LECT2 concentrations with diabetic retinopathy
Table 3 presents the results of uni- and multivariate logistic regres-
sion analyses to elucidate independent factors associated with DR. The
univariate regression model showed signiﬁcant positive correlations
between DR and duration of DM (P= 0.039), SBP (P= 0.016), HbA1c
(P = 0.038), insulin therapy (P b 0.001), DPN (P b 0.001), and DN
(P b 0.001), and signiﬁcant negative correlations between DR and log-
transformed TGs (P = 0.018), log-transformed γ-GTP (P = 0.022),
and serum LECT2 concentration (P b 0.001). There was no relationshipFig. 1.Distributions of serum leukocyte cell-derived chemotaxin 2 (LECT2) levels within the gro
retinopathy (DR, n = 95) compared to those without (non-DR, n= 135). (B) Serum LECT2 le
diabetic retinopathy (SDR, n= 65), pre-proliferative diabetic retinopathy (PPDR, n= 10), andbetween DR and gender, age, BMI, DBP, HDL cholesterol, FPG, ALT, or
oral medications. The multivariate regression model revealed that DR
was correlated independently with serum LECT2 concentration after
adjusting for gender, age, duration of DM, and BMI (Table 3, Model 1;
P b 0.001). Even after adjustments for SBP, log-transformed TGs,
HbA1c, log-transformed γ-GTP, insulin therapy, DPN, and DN, serum
LECT2 concentration was still strongly independently correlated with
DR (Table 3, Model 2; P b 0.001).
4. Discussion
The pathogenesis of DR includes angiogenesis and inﬂammation. Al-
though LECT2 is a secretory blood protein with anti-angiogenic and im-
munomodulatory effects, there has been no reported study that
associates circulating LECT2 concentrations with DR. Here, we per-
formed Spearman's rank correlation analysis to examine whether
changes in serum LECT2 concentration is associated with retinopathy
in participants with type 2 DM that indicated a negative correlation be-
tween serumLECT2 concentration and thepresence of DR.Other diabet-
ic microvascular complications, namely DPN and DN, were notups. (A) Serum LECT2 levels were signiﬁcantly decreased in the participants with diabetic
vels did not differ signiﬁcantly between the three stages of diabetic retinopathy: simple
proliferative diabetic retinopathy (PDR, n= 20).
Table 3
Logistic regression analysis for diabetic retinopathy.
Variable Univariate Multivariate Model 1 Multivariate Model 2
B Wald P
value
Odds ratio (95% CI) B Wald P
value
Odds ratio (95% CI) B Wald P
value
Odds ratio (95% CI)
LECT2 (ng/ml) −0.034 14.144 b0.001 0.966
(0.949–0.984)
−0.035 13.316 b0.001 0.965
(0.947–0.984)
−0.040 13.310 b0.001 0.961
(0.940–0.982)
Gender (women vs. men) 0.152 0.282 0.595 1.165
(0.664–2.042)
0.335 1.168 0.280 1.399
(0.761–2.570)
0.623 2.889 0.089 1.864
(0.909–3.821)
Age (10 y) 0.060 0.079 0.779 1.062
(0.698–1.614)
−0.126 0.261 0.610 0.882
(0.544–1.429)
−0.161 0.320 0.571 0.851
(0.488–1.486)
Duration of DM (y) 0.033 4.273 0.039 1.034
(1.002–1.066)
0.029 2.910 0.088 1.029
(0.996–1.064)
0.012 0.386 0.534 1.012
(0.974–1.052)
BMI (kg/m2) −0.022 0.455 0.500 0.979
(0.919–1.042)
0.016 0.192 0.661 1.016
(0.947–1.089)
0.022 0.284 0.594 1.022
(0.943–1.108)
SBP (10 mm Hg) 0.223 5.825 0.016 1.249
(1.043–1.497)
0.180 2.815 0.093 1.197
(0.970–1.476)
DBP (10 mm Hg) −0.083 0.434 0.510 0.920
(0.718–1.179)
HDL cholesterol (mg/dl) −0.006 0.434 0.510 0.994
(0.977–1.012)
TGs (mg/dl)a −1.502 5.610 0.018 0.223
(0.064–0.772)
−1.429 3.199 0.074 0.240
(0.050–1.147)
FPG (mg/dl) 0.001 0.101 0.751 1.001
(0.995–1.007)
HbA1c (%) 0.246 4.292 0.038 1.279
(1.013–1.614)
0.245 3.086 0.079 1.277
(0.972–1.677)
ALT (U/l) −0.009 1.263 0.261 0.991
(0.976–1.006)
γ-GTP (U/l)a −1.222 5.220 0.022 0.295
(0.103–0.841)
0.203 0.087 0.768 1.225
(0.317–4.738)
Insulin (no vs. yes) 1.417 14.894 b0.001 4.124
(2.008–8.467)
0.838 3.944 0.047 2.313
(1.011–5.290)
Biguanide (no vs. yes) −0.176 0.388 0.533 0.839
(0.482–1.459)
Statin (no vs. yes) 0.136 0.254 0.614 1.145
(0.676–1.942)
Fibrate (no vs. yes) −0.370 0.507 0.476 0.691
(0.250–1.911)
ACE-I and/or ARB (no vs.
yes)
0.427 2.493 0.114 1.532
(0.902–2.601)
DPN (no vs. yes) 1.156 16.521 b0.001 3.177
(1.819–5.547)
1.247 13.448 b0.001 3.481
(1.787–6.781)
DN (no vs. yes) 0.946 11.794 b0.001 2.574
(1.501–4.416)
0.742 4.877 0.027 2.099
(1.087–4.054)
a Log scale.
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DR and decreased serum LECT2 concentrations did not change marked-
ly after adjusting for known DR risk factors and potential confounders.
These results indicate that serum LECT2 concentration is speciﬁcally as-
sociated with the presence of retinopathy in people with DM.
A recent study reported that LECT2 inhibits VEGF165-signaling
through binding to VEGFR2 in human umbilical vein endothelial cells
[24]. The decreased circulating LECT2 concentration may contribute to
exacerbating VEGF/VEGFR2-signaling of the retinal endothelial cells in
DR. Theseﬁndings togetherwith the results of thepresent study suggest
that LECT2 plays an important suppressive role in retinal microvascular
dysfunction by reducing chronic micro-inﬂammation. Moreover, circu-
lating LECT2 concentration is not associated with the presence of DPN
and DN, although the contribution of VEGF to thesemicrovascular com-
plications was reported [28,29]. This difference might be explained by
vitreous VEGF-induced leukocyte–endothelial interaction in DR. Vitre-
ous VEGF also can induce intercellular adhesion molecule-1 expression
and leukocyte adhesion in retina [30]. The leukocyte–retinal endothelial
interaction plays an important role in the early phase of the develop-
ment of DR [31]. LECT2 was originally named for its possible neutrophil
chemotactic activity in vitro [15]. However, in the present study serum
LECT2 concentration was lower in the participants with DR than in
thosewithout. The study data imply that VEGF-induced leukocyte adhe-
sion is increased in lower circulating LECT2 circumstance and suggested
that the neutrophil chemotactic function of LECT2 differs between invivo and in vitro. Certainly this speculation is consistent with our previ-
ous study that the synovial membranes of arthritis-induced LECT2-deﬁ-
cient mice are more markedly inﬁltrated by neutrophils than in the
wild-typemice [19]. This study also revealed that serum LECT2 concen-
trations did not differ signiﬁcantly between the stages of DR.We consid-
er that the lower circulating LECT2 condition leads to the onset of DR
andmay be a risk factor for DR. Further investigation is needed to clarify
this issue. We intend to further investigate these possible molecular
mechanisms in DR.
We previously reported that increased serum LECT2 concentration is
positively correlated with obesity and insulin resistance but not corre-
lated with FPG and HbA1c after adjusting for potential confounders
[16]. The present study supported the abovementioned ﬁndings:
serum LECT2 concentrations in participants with DM were positively
correlatedwith BMI but not correlatedwith FPG andHbA1c. These ﬁnd-
ings indicated that LECT2 does not have a direct impact on the blood
glucose concentration. After adjustment of gender, age, duration of
DM, and BMI, serum LECT2 concentration was also correlated with
HDL cholesterol, ALT, and γ-GTP, which was consistent with our previ-
ous data based on the serum of healthy participants [16].
LECT2 is mainly secreted by hepatocyte. In this study, liver function
markers (ALT andγ-GTP)were correlatedwith serumLECT2 concentra-
tion but not with the presence of DR. The frequency of the use of oral
medications, including biguanide, was not correlated with serum
LECT2 concentration or the presence of DR. Moreover, serum LECT2
149A. Okumura et al. / Clinica Chimica Acta 463 (2016) 145–149concentration is more associated with the presence of DR than with
liver function markers. These results suggest that the liver function-in-
dependent LECT2 alterations are related to the onset of DR.
Limitations of this study included the relatively small number of par-
ticipants when divided according to the different vitreoretinal condi-
tions of DR, involvement only of a single center, and the study's non-
random, non-blinded nature. All these factors may be associated with
bias. Because this study is a cross-sectional case-control study, it is un-
certain whether the onset of DR leads to the decreased serum LECT2
concentration or the lower serum LECT2 concentration condition leads
to the onset of DR. This could be resolved by comparing the serum
LECT2 concentration before and after the onset of DR in a multicenter
cohort study.
We did not conduct an interview regarding life style factors in this
study. However, we have previously reported that alcohol consumption
was not statistically associated with serum LECT2 concentration in
healthy subjects [16]. Additionally, we obtained data on the smoking
and coffee-drinking habits from the lifestyle questionnaire ﬁlled by
the healthy subjects and assessed the relationship between serum
LECT2 concentration and these habits. We found that these habits
were not associated with serum LECT2 concentration in healthy sub-
jects (unpublished data). To date only one human study has been re-
ported on the effect of exercise on circulating LECT2 concentration in a
conference presentation [32]. This report indicates that cardiorespirato-
ry ﬁtness and physical activity are not independently associated with
plasma LECT2 concentration in human. On the other hand, Lan et al. re-
ported that mouse serum LECT2 concentration was signiﬁcantly re-
duced by exercise [17]. Future experiments are needed to validate this
ﬁnding.
Thiswas theﬁrst study to examine the associations of DRwith LECT2
and showed that serum LECT2 concentrations were signiﬁcantly lower
in people with DR compared with those with DM but without DR. This
ﬁnding suggests that circulating LECT2 is speciﬁcally associated with
the presence of DR and plays a functional role in the pathogenesis of
DR. The possible causal relationship between low circulating LECT2
and the presence of DRmaybe due to VEGF-signaling inhibition and im-
munomodulatory properties of LECT2.
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